

## THYROCARE TECHNOLOGY LTD.

ISIN CODE: INE594H01019

BSE: 539871

NSE: THYROCARE

CMP: 1,121.45

### OVERVIEW

Tue, 25<sup>th</sup> Nov '21

- Thyrocare is one of the leading pan-India diagnostic chains that conduct an array of medical diagnostic tests and profiles of tests that center on early detection and management of disorders and diseases.
- The company has three business segments: Diagnostic Testing Services, Imaging Services, and Other.
- The Other business segment provides miscellaneous services.
- The pioneers in the private sector offering entire range of laboratory services across the nation.
- The company earns the vast majority of its revenue in India.

### ACHIEVEMENTS

- Has built in capacity to process and report more than 50000 swab samples, spread across three dedicated COVID testing laboratories.
- Had a network of about 4,500 service providers, comprised of TSPs, TAGs, OLCs, HVCs spread across more than 250 districts covering all the states.

### KEY STRENGTH

- Portfolio of specialized tests with an emphasis on wellness and preventive healthcare.
- Multi-lab model driving volume growth and economies of scale.
- Pan-India collection network supported by logistics capabilities and information technology infrastructure.
- Capital efficiencies in our diagnostic testing business.
- Experienced senior leadership and management team.
- leaders in preventive care diagnostic test offerings

### GROWTH STRATEGIES

- Will continue to focus on growth of its wellness and preventive offerings and expansion of test offerings through aggressive price rationalization.
- Focusing a significant proportion of marketing efforts on preventive diagnostic and wellness offerings.
- Intend to expand diagnostic test offerings through the acquisition of new technologies, including both instruments and processes.
- Intend to expand our presence in eastern part of India by setting up NABL accredited Covid testing laboratory in Kolkata in few months.

### FUTURE OUTLOOK

- To add 10 more RPL for existing 15 RPL to improve the reach and go closer to customers for a better Turnaround Time
- Focus and aggressively add to the network of 500 committed franchisees to 2000 in this FY.
- Intend to set-up Zonal Processing Laboratories (ZPLs), strategically to perform advance tests so as to cover the country
- They Plan on targeted expansion by continuing to open RPLs in locations in close proximity to rail or road networks and in markets that are expected to generate high volumes of samples.

### FINANCIAL HIGHLIGHTS

- Revenue from operations increased from Rs. 434.26 Cr in Fiscal 2020 to Rs. 494.62 Cr in Fiscal 2021, registering a growth of 14%.
- However EBITDA has decreased by -0.77% to Rs. 170.39 Cr in FY-21, compared to Rs. 171.72 Cr in FY-20.
- PAT has reached to Rs. 113.15 Cr in FY-21, an increase of 28%, against Rs. 88.40 Cr in FY-20.
- The total dividend for the year 2020-21 was Rs. 25/- per share, 110.34 % of the Company's Stand-alone Profit after tax.

Growth Rates % (Compound Annual)	1 Yr	3 Yr	5 Yr	10yr
Revenue	13.9	11.6	15.5	-
Operating Income	-0.4	3.9	13.2	-
Earnings/Share	27.9	7.2	16.3	-
Dividends	-60.0	0.0	-	-
Book Value/Share	16.5	-0.7	2.5	-
Stock Total Return	6.0	29.0	12.6	-
Market +/-	-22.2	12.6	1.8	-

Valuation Ratio	Current	5Yr Avg	Ind	Mkt.
Price/Earnings	29.1	-	56.6	16.0
Forward P/E	-	-	-	-
Price/Cash Flow	36.0	-	-	10.4
Price/Free Cash Flow	47.3	-	-	-
Dividend Yield %	2.2	2.0	0.5	2.6
Price/Book	12.2	-	15.6	2.2
Price/Sales	9.4	-	12.2	-

Profitability Ratio	Current	5Yr Avg	Ind.	Mkt.
Return on Equity	45.0	20.5	33.8	15.4
Return on Asset	36.7	17.9	24.4	5.6
Gross Margin	70.5	71.8	74.2	-
Operating Margin	36.8	32.2	29.2	-
Net Margin	32.5	20.9	21.0	21.6
Inventory Turns	7.7	6.5	8.1	-
Fixed Asset Turns	3.6	2.3	4.6	-

Financial Position (INR)	03-20(Mil.)	03-21 (Mil.)
Cash	132	61
Inventories	234	213
Receivables	—	—
Current Assets	2,381	2,547
Fixed Assets	1,601	1,783
Intangibles	1,013	1,012
Total Assets	5,458	5,835
Payables	400	289
Short-Term Debt	5	5
Current Liabilities	951	700
Long-Term Debt	0	0
Total Liabilities	1,185	1,011
Total Equity	4,273	4,824

Source: Company filings & Analyst Research

**Disclaimer:** The analysis is only for information purposes only. Please consult your financial advisor, agent and broker before acting on any information. We may or may not have positions in the stock. We would not be responsible for the profit/loss resulting from this analysis.